Co-primary endpoints were secukinumab superiority over placebo for week 12 PASI 75 ( 75 % reduction in Psoriasis Area and Severity Index ) and IGA mod 2011 ( 2011 modified Investigator 's Global Assessment ) 0/1 response rates .